Semaglutide plus fasting plus tesofensine: what the evidence actually says

What did @dr_jonesdc actually say?

The creator, who presents as a chiropractor, describes switching patients from tirzepatide (Mounjaro) to tesofensine when GLP-1 medications are not tolerated or contraindicated. They call tesofensine their "favorite go-to backup option" and describe it as a "triple monoamine reuptake inhibitor" that raises dopamine, norepinephrine, and serotonin to cut hunger and boost metabolism. They also promise patients can eventually wean off all medications and maintain weight loss permanently.

The framing here is worth pausing on. This is a chiropractor positioning tesofensine as a clinical alternative to a FDA-approved GLP-1 drug, in a TikTok video, without discussing dosing, monitoring, cardiovascular risks, or regulatory status. That context matters before we assess the science.

Does the science back this up?

Partially, but the evidence for tesofensine is much thinner than this video implies, and the drug is not FDA-approved for weight loss in the United States. The mechanism description is accurate. The clinical picture is more complicated.

Tesofensine was originally developed for Parkinson's disease and later studied for obesity. A 2008 phase 2 trial by Astrup et al. published in The Lancet showed 0.5 mg daily produced roughly 12.8 kg weight loss over 24 weeks versus 2.2 kg for placebo. That sounds impressive. What the video skips: participants in the tesofensine groups experienced significantly elevated heart rate and blood pressure, dry mouth, insomnia, and nausea. A 2012 review by Schoedel and Sellers in CNS Drugs flagged abuse potential concerns given its dopaminergic activity. Tesofensine has never completed a phase 3 trial in the United States. It is not approved by the FDA. It exists in a regulatory gray zone, available through compounding pharmacies in some markets.

What did they get wrong (or right)?

The mechanism description is genuinely accurate. Tesofensine does inhibit reuptake of dopamine, norepinephrine, and serotonin. The claim that this combination reduces both physical hunger and "mental food chatter" has some biological plausibility: dopaminergic signaling affects reward-driven eating, and norepinephrine plays a role in appetite suppression. Credit where it is due.

But several things here deserve pushback. First, the video presents tesofensine as a routine clinical alternative to tirzepatide without mentioning its cardiovascular side effect profile. For patients who already have metabolic disease, elevated heart rate and blood pressure are not minor footnotes. Second, the contraindications listed for GLP-1s, specifically thyroid cancer history and pancreatitis, are real, but the video implies tesofensine carries no comparable baggage. That is misleading. Third, and most significantly, the claim that patients can "wean off eventually off of all the medications and actually maintain your weight for the rest of your life" is not supported by current evidence for any weight loss drug category. Obesity is a chronic condition. Regain after drug discontinuation is well-documented across GLP-1 and non-GLP-1 agents alike, including in the STEP 1 trial extension data (Wilding et al., 2022, New England Journal of Medicine).

What should you actually know?

Tesofensine is a real compound with real phase 2 data, but it is not an FDA-approved drug, and calling it a straightforward "backup" to tirzepatide glosses over that entirely. Anyone encountering this video should understand a few things clearly.

GLP-1 intolerability is common and worth discussing with a licensed prescriber who can review your full cardiovascular and psychiatric history before suggesting a stimulant-adjacent drug like tesofensine. The dopamine reuptake inhibition that makes tesofensine interesting for weight loss is also what raises questions about dependency potential and cardiovascular strain. These are not hypothetical concerns.

The "wean off all medications" framing is popular on social media and genuinely appealing, but the physiology of obesity does not work that way for most people. Presenting permanent medication-free weight maintenance as a standard expected outcome sets patients up for self-blame when biology reasserts itself. That framing should be challenged, not amplified.

If you did not tolerate tirzepatide, there are FDA-approved options worth exploring with a physician, including semaglutide at different titration schedules, or older agents like bupropion-naltrexone (Contrave), which has a more established regulatory and safety record than tesofensine in the US context.